<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Among 90,128 patients with <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> in the years 1976-1989 <z:hpo ids='HP_0011009'>acute</z:hpo> non lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (ANLL) was diagnosed in 351 patients (0.4%) and in 15 (4.3%) of them ANLL was secondary <z:hpo ids='HP_0002664'>neoplasm</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">Secondary ANLL</z:e> occurred in 10% of <z:hpo ids='HP_0000001'>all</z:hpo> the 148 secondary <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> observed at that period of time and constituted 6.7% of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary malignancy</z:e> in patients with <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> and 43% in patients with myeloproliferative syndromes as a first malignant <z:hpo ids='HP_0002664'>neoplasm</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In the treatment of first <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> radiotherapy was applied in 11 persons, in combination with chemotherapy in 7 of them and chemotherapy alone was given to 4 patients </plain></SENT>
<SENT sid="3" pm="."><plain>The appearance of the <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary ANLL</z:e> was usually preceded by the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Morphologically, <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary ANLL</z:e> belonged mostly to M6 and M4 (8 patients) according to FAB classification </plain></SENT>
<SENT sid="5" pm="."><plain>The course of ANLL was fulminant and the disease was completely resistant to the treatment </plain></SENT>
</text></document>